Grifols celebrates 25^th anniversary of its Diagnostic R&D center in Bizkaia, a key driver of its sector leadership

Barcelona, Spain, May 29, 2025 - Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, today celebrated the 25^th anniversary of its Derio (Bizkaia) facility, a center specialized in the development of in vitro diagnostic systems. For more than two decades, the campus has contributed to improving patient outcomes and reinforcing the company’s leadership in transfusion medicine.

The commemorative event was held at the Bizkaia Technology Park in Derio and was attended by several dignitaries, including Elixabete Etxanobe, General Deputy of Bizkaia; Mikel Jauregi, Basque Government Minister of Industry, Energy Transition and Sustainability; Esther Apraiz, Mayor of Derio; Ainara Basurko, Provincial Deputy for Economic Promotion; Jaione Ganzarain, Basque Government Deputy Minister of Technology, Innovation and Digital Transformation, and Ander Caballero, Secretary General for Foreign Action and Euskadi Global.

Grifols is a global leader in transfusion medicine. Each year, its solutions analyze tens of millions of blood and plasma samples to ensure they are pathogen-free and compatible between donor and recipient.

The Derio campus is currently developing next-generation platforms for the Diagnostic business unit that will enable Grifols to offer the three most widely used diagnostic technologies in transfusion medicine — molecular testing, immunoassays, and blood typing — in a fully automated format for blood banks and laboratories around the world. Grifols plans to launch new generations of these assays and technologies over the coming years.

In recent years, the company has expanded its presence in clinical diagnostics through the development of innovative technologies, enabling steady progress in the in vitro diagnostics (IVD) sector — an area in which the Derio center plays a fundamental role.

Founded in 2000 under the name Progenika and acquired by Grifols in 2013, the Derio research and manufacturing center has made significant contributions to the healthcare sector. In 2004, it launched the first CE-marked genetic test for familial hypercholesterolemia, followed in 2008 by its first blood genotyping product, now a standard in the field.

More recently, in 2020 and in record time, this Grifols center developed a highly sensitive molecular test to detect the SARS-CoV-2 virus, which was used in many hospitals across Spain during the global COVID-19 pandemic. Additionally, the Derio facility developed the AlphaID™ test, designed to detect the most prevalent variants associated with alpha₁-antitrypsin deficiency (alpha-1), a leading cause of chronic obstructive pulmonary disease (COPD), a serious respiratory condition.

Grifols’ expanding clinical diagnostics portfolio also includes the Promonitor^® line of assays, which measure levels of biologic drugs and anti-drug antibodies in patients undergoing treatment for chronic inflammatory diseases and other conditions. These tests help monitor patients receiving biologic therapies, enabling dose adjustments and improving treatment effectiveness.

“Since the beginning, Grifols has been defined by its entrepreneurial and innovative spirit. We remain committed to innovation as a way to deliver better and more effective solutions for patients,” said Nacho Abia, Grifols Chief Executive Officer. “Our Derio team has proven to be at the forefront of blood genotyping and, more recently, clinical diagnostics. They will continue to play a key role in the company’s future.”

Diagnostic growth

Grifols’ Diagnostic business unit grew by 5.2% in the first quarter of 2025 compared to the same period last year, reaching revenues of €170 million.

“As part of our five-year strategic plan, we are developing the diagnostic solutions of the future to enhance the safety and reliability of transfusions and improve the diagnosis of clinical conditions, ultimately contributing to a better quality of life for both patients and donors,” said Antonio Martínez, President Diagnostic Business Unit. “We have a highly qualified and committed team that will help revolutionize disease diagnostics and transfusion health for the benefit of science and the patient community.”

Today, more than 95 professionals work at the Derio facility, primarily focused on research and development of in vitro diagnostic solutions. In addition to R&D and the development and manufacturing of diagnostic tests, the campus also conducts patient sample analysis in therapeutic areas where Grifols operates.